Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini,Aleksandra Markovets,Lucy Ireland,Daniel O’Neill,Benjamin Phillips,Man Xu,Matthias Pfeifer,Tereza Vaclova,Matthew J. Martin,Ludovic Bigot,Luc Friboulet,Ryan Hartmaier,Maria E. Cuomo,Simon T. Barry,Paul D. Smith,Nicolas Floc’h

crossref（2024）

Cited 0|Views4

Abstract

Table S1: Statistical comparison between treatment arms for the on-treatment phase in PC9 PIK3CAm xenograft models described in Figure 5E.

Translated text

求助PDF

上传PDF

Bibtex

AI Read Science

AI Summary

AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.

Example

Background

Key content

Introduction

Methods

Results

Related work

Fund

Key content

Pretraining has recently greatly promoted the development of natural language processing (NLP)
We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance

Upload PDF to Generate Summary

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Chat Paper

【要点】：本文探讨了在EGFR突变驱动的非小细胞肺癌中，通过AKT抑制克服奥西替尼耐药性的策略，并研究了PIK3CA/PTEN变异的影响。

【方法】：作者采用分子生物学方法和药物筛选技术，研究了AKT抑制剂与奥西替尼联用对EGFRm驱动的非小细胞肺癌细胞系的影响。

【实验】：实验在PC9 PIK3CAm异种移植模型中进行，通过Table S1展示了治疗期间不同处理组间的统计学比较结果。